Etrolizumab outperforms placebo in achieving clinical remission for Crohn's disease
Written By : Dr.Niharika Harsha B
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-10-19 14:45 GMT | Update On 2022-10-19 14:45 GMT
| Maintenance phase TEA | etrolizumab, n=217 | Placebo, n=217 |
| Injection site erythema | 6 | 14 |
| Arthralgia | 5 | 8 |
| Headache | 5 | 7 |
- The most common serious adverse event was an exacerbation of Crohn's disease seen in 14 [6%] of 217 patients taking a placebo and four [2%] of 217 patients taking 105 mg etrolizumab in the maintenance cohort.
Thus, the trial revealed that etrolizumab was successful in attaining clinical remission and endoscopic improvement in a significantly higher proportion of patients with moderately to severely active Crohn's disease during the maintenance phase but the same could not be achieved during the induction phase.
Further reading: https://doi.org/10.1016/S2468-1253(22)00303-X
Sandborn WJ, Panés J, Danese S, et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomized, placebo-controlled, double-blind, phase 3 trial [published online ahead of print, 2022 Oct 11]. Lancet Gastroenterol Hepatol. 2022; S2468-1253(22)00303-X.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd